Not provided
Not provided
| ID | Type | Description | Link |
|---|---|---|---|
| CDR0000631252 | Registry Identifier | PDQ (Physician Data Query) |
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
RATIONALE: Studying samples of blood from patients with cancer in the laboratory may help doctors learn more about the effect of bevacizumab and VEGF on platelet clustering.
PURPOSE: This research study is looking at the effect of bevacizumab and VEGF on platelet clustering in patients with cancer who are receiving bevacizumab.
OBJECTIVES:
OUTLINE: Blood samples are collected before and after bevacizumab infusion. Samples are analyzed for measurements of platelet aggregation, coagulation parameters, and endothelial activation (e.g., fibrin fragment F1 and 2, thrombin and antithrombin complex, soluble P-selectin, Von Willebrand factor and factor VIII, tissue factor, and endothelin 1).
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Type | Description | Arm Group Labels | Other Names |
|---|---|---|---|---|
| bevacizumab | Biological | |||
| coagulation study | Other | |||
| laboratory biomarker analysis | Other | |||
| platelet aggregation test | Other |
| Measure | Description | Time Frame |
|---|---|---|
| Influence of bevacizumab on platelet aggregation | ||
| Influence of VEGF on platelet aggregation | ||
| Influence of VEGF or bevacizumab on cyclooxygenesis | ||
| Correlation between medication sequence and platelet aggregation |
Not provided
Not provided
DISEASE CHARACTERISTICS:
PATIENT CHARACTERISTICS:
PRIOR CONCURRENT THERAPY:
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
Not provided
| Name | Affiliation | Role |
|---|---|---|
| Roger von Moos, MD | Kantonsspital Graubuenden | Principal Investigator |
| Facility | Status | City | State | ZIP | Country | Contacts |
|---|---|---|---|---|---|---|
| Kantonsspital Graubuenden | Recruiting | Chur | CH-7000 | Switzerland |
Not provided
| ID | Term |
|---|---|
| D000068258 | Bevacizumab |
| D001760 | Bleeding Time |
| D010974 | Platelet Aggregation |
| ID | Term |
|---|---|
| D061067 | Antibodies, Monoclonal, Humanized |
| D000911 | Antibodies, Monoclonal |
| D000906 | Antibodies |
| D007136 | Immunoglobulins |
| D007162 | Immunoproteins |
| D001798 | Blood Proteins |
| D011506 | Proteins |
| D000602 | Amino Acids, Peptides, and Proteins |
| D012712 | Serum Globulins |
| D005916 | Globulins |
| D010979 | Platelet Function Tests |
| D006403 | Hematologic Tests |
| D019411 | Clinical Laboratory Techniques |
| D019937 | Diagnostic Techniques and Procedures |
| D003933 | Diagnosis |
| D008919 | Investigative Techniques |
| D001790 | Blood Physiological Phenomena |
| D002943 | Circulatory and Respiratory Physiological Phenomena |
| D018056 | Hemorheology |
| D015539 | Platelet Activation |
| D006487 | Hemostasis |
Not provided
Not provided